The trial will involve 42 patients whose breast cancer has spread to other parts of the body.
The acquisition, which also includes GuideStar Research and BTC of New Bedford, was financed through investor funding.
The companies will address high costs for site activation and enrolment barriers linked to NASH drug trials.
The partners will facilitate diversified participation and improve health equity for decentralised and hybrid clinical trials.
The trial will test the safety, tolerability and immunogenicity of two dose levels of the vaccine given as a booster to Vaxzevria.
Give your business an edge with our leading industry insights.
Subjects will receive a first dose of the Pfizer-BioNTech vaccine and a second dose of either Pfizer, Novavax or Moderna.
Vixotrigine 200mg dose met the primary endpoint while 350mg failed to achieve the goal, with both doses being well tolerated.
A statistically significant improvement in symptoms and signs was observed at day 14 and sustained through day 84.
The trial is the first to compare a Covid-19 vaccine candidate with Pfizer’s Covid-19 vaccine in this patient population.
In 96% of participants, vaccination led to an enhanced immune memory response against the Covid-19 virus.